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1. Which of the following classes of antimicrobial drugs is 
least likely to be used in European countries?
A.   Lincosamides
B.   Fluoroquinolones
C.   Cotrimoxazole
D.   Macrolides
2. Which of the following regions in Europe has the highest 
outpatient utilization of antimicrobial drugs?
A.   Southern
B.   Northern
C.   Eastern
D.   Central
3. Which of the following is the most widely used 
antimicrobial drug class in Europe?
A.   Macrolides
B.   Penicillins
C.  Nonpenicillin beta-lactams
D.   Fluoroquinolones
4. Which of the following European countries showed both 
the greatest use of antimicrobial drugs in ambulatory care 
and the highest resistance proportions?
A.   France
B.   Croatia
C.   Italy
D.   Greece
5. Among European countries with high antimicrobial drug 
resistance rates, a robust and consistent association was 
most likely to be found between utilization and resistance for 
which of the following drugs?
A.   Penicillins and macrolides
B.   Lincosamides and macrolides
C.   Penicillins and streptogramins
D.   Penicillins and ?  uoroquinolones
1. The activity supported the learning objectives. 
Strongly Disagree Strongly Agree 
1 5 4 3 2
2. The material was organized clearly for learning to occur.
Strongly Disagree Strongly Agree
5 4 3 2 1
3. The content learned from this activity will impact my practice.
Strongly Disagree Strongly Agree
5 4 3 2 1
4. The activity was presented objectively and free of commercial bias.
Strongly Disagree Strongly Agree
5 4 3 2 1
Our study confronts the use of antimicrobial agents in 
ambulatory care with the resistance trends of 2 major patho-
gens, Streptococcus pneumoniae and Escherichia coli, in 
21 European countries in 2000–2005 and explores whether 
the notion that antimicrobial drug use determines resistance 
can be supported by surveillance data at national aggre-
gation levels. The data obtained from the European Sur-
veillance of Antimicrobial Consumption and the European 
Antimicrobial Resistance Surveillance System suggest that 
variation of consumption coincides with the occurrence of 
resistance at the country level. Linear regression analysis 
showed that the association between antimicrobial drug use 
and resistance was speciﬁ  c and robust for 2 of 3 compound 
pathogen combinations, stable over time, but not sensitive 
enough to explain all of the observed variations. Ecologic 
studies based on routine surveillance data indicate a rela-
tion between use and resistance and support interventions 
designed to reduce antimicrobial drug consumption at a na-
tional level in Europe.
F
or the past 60 years, antimicrobial chemotherapy has 
been the mainstay of medical intervention against 
infectious diseases caused by bacterial pathogens. The 
continuous decline of therapeutic effectiveness as a re-
sult of extensive use of antimicrobial chemotherapy has 
been long predicted and seems inescapable (1). Many 
surveillance efforts have over the last decade (1997–
2007)  drawn  attention  to  this  phenomenon  (2–5).  At 
the same time, the once-abundant supply of new and 
improved antimicrobial compounds has worn thin, as 
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Learning Objectives
Upon completion of this activity, participants will be able to:
Identify the classes of antimicrobial drugs most commonly used in Europe. • 
Describe patterns of antimicrobial drug use across regions in Europe. • 
Identify the most widely used antimicrobial drugs by country in Europe. • 
List European countries that show the highest antimicrobial drug resistance proportions. • 
Describe the association between antimicrobial drug use and the emergence of resistance. • 
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